{"id":19783,"date":"2023-04-11T14:32:00","date_gmt":"2023-04-11T06:32:00","guid":{"rendered":"https:\/\/flcube.com\/?p=19783"},"modified":"2024-12-25T14:41:38","modified_gmt":"2024-12-25T06:41:38","slug":"hua-medicine-partners-with-111-inc-for-dorzagliatin-sales-and-distribution-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19783","title":{"rendered":"Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China"},"content":{"rendered":"\n<p>China-based Hua Medicine (<a href=\"https:\/\/www.google.com\/finance\/quote\/2552:HKG\">HKG: 2552<\/a>) has announced a sales and distribution agreement with online pharma retailer 111 Inc., enabling the latter to sell Hua Medicine&#8217;s dorzagliatin on its platform from April 7, 2023, to December 31, 2023. Hua Medicine will charge a fee of not more than RMB 40 million (USD 5.8 million) for this partnership.<\/p>\n\n\n\n<p><strong>Dorzagliatin: A First-in-Class Glucokinase Activator (GKA)<\/strong><br>Dorzagliatin is a first-in-class glucokinase activator (GKA) designed to control the progressive degenerative characteristics of diabetes by restoring glucose homeostasis in patients with type 2 diabetes mellitus. Hua Medicine obtained global development and marketing rights to the molecule from Roche in December 2011. GK is a blood glucose sensor that plays a crucial role in adjusting endocrine function according to changes in blood glucose concentration.<\/p>\n\n\n\n<p><strong>Commercialization Efforts and Partnerships<\/strong><br>In preparation for the commercialization of dorzagliatin, Hua Medicine signed an agreement with Germany-based Bayer in August 2020. Bayer is responsible for marketing, promotion, and medical education activities in China in a deal worth up to RMB 4.5 billion (USD 633.5 million). Hua Medicine retains the Marketing Authorization Holder (MAH) status for the drug. Additionally, Hua Medicine enlisted WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/603259:SHA\">SHA: 603259<\/a>), for commercial-scale manufacturing in February of last year.<\/p>\n\n\n\n<p><strong>Market Approval and Launch of Dorzagliatin<\/strong><br>A Category 1 innovative drug, dorzagliatin secured its first market approval in China in October 2022 to improve blood glucose control in adults with type 2 diabetes. It was officially launched in Shanghai in the same month, priced at RMB 420 (USD 61) per box, making it accessible to patients in need.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Hua Medicine (HKG: 2552) has announced a sales and distribution agreement with online pharma&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,93],"tags":[1933,39,88,1159,308,1078,362,1998],"class_list":["post-19783","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","category-digital","tag-111-inc","tag-diabetes","tag-e-commerce","tag-hkg-2552","tag-hua-medicine","tag-sha-603259","tag-wuxi-apptec","tag-wuxi-sta"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Hua Medicine (HKG: 2552) has announced a sales and distribution agreement with online pharma retailer 111 Inc., enabling the latter to sell Hua Medicine&#039;s dorzagliatin on its platform from April 7, 2023, to December 31, 2023. Hua Medicine will charge a fee of not more than RMB 40 million (USD 5.8 million) for this partnership.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19783\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19783\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T06:32:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-25T06:41:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19783#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19783\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China\",\"datePublished\":\"2023-04-11T06:32:00+00:00\",\"dateModified\":\"2024-12-25T06:41:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19783\"},\"wordCount\":264,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"111 Inc\",\"Diabetes\",\"E-commerce\",\"HKG: 2552\",\"Hua Medicine\",\"SHA: 603259\",\"WuXi AppTec\",\"WuXi STA\"],\"articleSection\":[\"Company\",\"Deals\",\"Digital\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19783#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19783\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19783\",\"name\":\"Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-11T06:32:00+00:00\",\"dateModified\":\"2024-12-25T06:41:38+00:00\",\"description\":\"China-based Hua Medicine (HKG: 2552) has announced a sales and distribution agreement with online pharma retailer 111 Inc., enabling the latter to sell Hua Medicine's dorzagliatin on its platform from April 7, 2023, to December 31, 2023. Hua Medicine will charge a fee of not more than RMB 40 million (USD 5.8 million) for this partnership.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19783#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19783\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19783#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Hua Medicine (HKG: 2552) has announced a sales and distribution agreement with online pharma retailer 111 Inc., enabling the latter to sell Hua Medicine's dorzagliatin on its platform from April 7, 2023, to December 31, 2023. Hua Medicine will charge a fee of not more than RMB 40 million (USD 5.8 million) for this partnership.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19783","og_locale":"en_US","og_type":"article","og_title":"Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=19783","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-11T06:32:00+00:00","article_modified_time":"2024-12-25T06:41:38+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19783#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19783"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China","datePublished":"2023-04-11T06:32:00+00:00","dateModified":"2024-12-25T06:41:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19783"},"wordCount":264,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["111 Inc","Diabetes","E-commerce","HKG: 2552","Hua Medicine","SHA: 603259","WuXi AppTec","WuXi STA"],"articleSection":["Company","Deals","Digital"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19783#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19783","url":"https:\/\/flcube.com\/?p=19783","name":"Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-11T06:32:00+00:00","dateModified":"2024-12-25T06:41:38+00:00","description":"China-based Hua Medicine (HKG: 2552) has announced a sales and distribution agreement with online pharma retailer 111 Inc., enabling the latter to sell Hua Medicine's dorzagliatin on its platform from April 7, 2023, to December 31, 2023. Hua Medicine will charge a fee of not more than RMB 40 million (USD 5.8 million) for this partnership.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19783#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19783"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19783#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19783"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19783\/revisions"}],"predecessor-version":[{"id":19786,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19783\/revisions\/19786"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}